Tampered Data Cast Shadow on Drug Trial

A clinical trial led by cardiologist Hiroaki Matsubara of Kyoto Prefectural University of Medicine indicated that the blockbuster hypertension drug valsartan lowers the risk of stroke and angina for some patients. A university investigation, however, concluded that data had been manipulated; after reanalysis, the reduced risk of stroke and angina disappeared. The paper was retracted and Matsubara resigned from the university. But the fallout continues: The scandal has eroded confidence in Japan's biomedical research and raised concerns about cozy ties between researchers and drug companies.

Read the Full Text. (Login may be required.)

Posted in Health, People & Events, Asia/Pacific